[B01AD01, streptokinase, Propylthiouracil may increase the anticoagulant activities of Streptokinase.]
[L04AA04, rabbit anti-human T-lymphocyte globulin, The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Propylthiouracil.]
[L01AD04, streptozocin, The risk or severity of adverse effects can be increased when Streptozocin is combined with Propylthiouracil.]
[L04AA27, fingolimod, Propylthiouracil may increase the immunosuppressive activities of Fingolimod.]
[J01EC01, sulfamethoxazole, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Propylthiouracil.]
[M04AB02, sulfinpyrazone, The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Propylthiouracil.]
[A10BB04, glibornuride, The therapeutic efficacy of Glibornuride can be decreased when used in combination with Propylthiouracil.]
[L01BB02, mercaptopurine, Propylthiouracil may decrease the excretion rate of Mercaptopurine which could result in a higher serum level.]
[N06DA01, tacrine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Tacrine is combined with Propylthiouracil.]
[L01CB02, teniposide, The risk or severity of adverse effects can be increased when Teniposide is combined with Propylthiouracil.]
[R03CC03, terbutaline, The risk or severity of adverse effects can be increased when Terbutaline is combined with Propylthiouracil.]
[B01AE07, dabigatran etexilate, Propylthiouracil may increase the anticoagulant activities of Dabigatran etexilate.]
[L04AX02, thalidomide, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Thalidomide.]
[R03DA07, theobromine, Propylthiouracil may decrease the excretion rate of Theobromine which could result in a higher serum level.]
[R03DA04, theophylline, Propylthiouracil may decrease the excretion rate of Theophylline which could result in a higher serum level.]
[L01XX41, eribulin, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Eribulin.]
[L01AC01, thiotepa, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Thiotepa.]
[L01BB03, thioguanine, The risk or severity of adverse effects can be increased when Tioguanine is combined with Propylthiouracil.]
[B01AC05, ticlopidine, The risk or severity of bleeding can be increased when Ticlopidine is combined with Propylthiouracil.]
[A10BB05, tolazamide, The therapeutic efficacy of Tolazamide can be decreased when used in combination with Propylthiouracil.]
[V04CA01, tolbutamide, The therapeutic efficacy of Tolbutamide can be decreased when used in combination with Propylthiouracil.]
[C01DX11, trapidil, The risk or severity of bleeding can be increased when Trapidil is combined with Propylthiouracil.]
[N06AX05, trazodone, The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Trazodone.]
[L01XF01, tretinoin, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Tretinoin.]
[S01BA05, triamcinolone, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Triamcinolone.]
[N05CD05, triazolam, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propylthiouracil is combined with Triazolam.]
[C03AA06, trichlormethiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Trichlormethiazide is combined with Propylthiouracil.]
[S01AD02, trifluridine, The risk or severity of adverse effects can be increased when Trifluridine is combined with Propylthiouracil.]
[D07AC02, fluclorolone, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Fluclorolone.]
[R03BA07, mometasone, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Mometasone.]
[J01EA01, trimethoprim, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Trimethoprim is combined with Propylthiouracil.]
[N06AA06, trimipramine, The risk or severity of Cardiac Arrhythmia can be increased when Propylthiouracil is combined with Trimipramine.]
[R03DX07, roflumilast, Roflumilast may increase the immunosuppressive activities of Propylthiouracil.]
[L04AA26, belimumab, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Belimumab.]
[L01EX04, vandetanib, The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Vandetanib.]
[B01AD04, urokinase, Propylthiouracil may increase the anticoagulant activities of Urokinase.]
[L04AA28, belatacept, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Belatacept.]
[B01AF01, rivaroxaban, Propylthiouracil may increase the anticoagulant activities of Rivaroxaban.]
[B01AC24, ticagrelor, Propylthiouracil may increase the anticoagulant activities of Ticagrelor.]
[L01CA01, vinblastine, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Vinblastine.]
[L01CA02, vincristine, The risk or severity of adverse effects can be increased when Vincristine is combined with Propylthiouracil.]
[L01CA03, vindesine, The risk or severity of adverse effects can be increased when Vindesine is combined with Propylthiouracil.]
[B03BA01, vitamin B12, The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Propylthiouracil.]
[B01AA03, warfarin, Propylthiouracil may increase the anticoagulant activities of Warfarin.]
[S01AA13, fusidic acid, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propylthiouracil is combined with Fusidic acid.]
[J05AF01, zidovudine, The risk or severity of adverse effects can be increased when Zidovudine is combined with Propylthiouracil.]
[J05AE02, indinavir, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Indinavir is combined with Propylthiouracil.]
[L01EC01, vemurafenib, The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Vemurafenib.]
[M05BA03, pamidronic acid, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Propylthiouracil.]
[L01FX05, brentuximab vedotin, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Brentuximab vedotin.]
[L01ED01, crizotinib, The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Crizotinib.]
[B01AE01, desirudin, Propylthiouracil may increase the anticoagulant activities of Lepirudin.]
[M05BA06, ibandronic acid, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propylthiouracil is combined with Ibandronate.]
[L04AA34, alemtuzumab, The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Propylthiouracil.]
[N02BA01, aspirin, The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Propylthiouracil.]
[L01EJ01, ruxolitinib, The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Ruxolitinib.]
[L03AB11, peginterferon alfa-2a, The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Propylthiouracil.]
[L01FA01, rituximab, The risk or severity of adverse effects can be increased when Rituximab is combined with Propylthiouracil.]
[L01EK01, axitinib, The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Axitinib.]
[H02AB11, prednylidene, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Prednylidene.]
[L01BC07, azacitidine, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Azacitidine.]
[L04AX01, azathioprine, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Azathioprine.]
[L01BC05, gemcitabine, The risk or severity of adverse effects can be increased when Gemcitabine is combined with Propylthiouracil.]
[M03BX01, baclofen, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Baclofen is combined with Propylthiouracil.]
[J07BK01, varicella-zoster virus vaccine live (Oka-Merck) strain, The risk or severity of infection can be increased when Varicella zoster vaccine (live/attenuated) is combined with Propylthiouracil.]
[L01FX02, gemtuzumab ozogamicin, The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Propylthiouracil.]
[L01XG02, carfilzomib, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Carfilzomib.]
[L01EA04, bosutinib, The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Bosutinib.]
[L04AA31, teriflunomide, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Teriflunomide.]
[B01AX01, defibrotide, Propylthiouracil may increase the anticoagulant activities of Defibrotide.]
[L04AA22, abetimus, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Abetimus.]
[H02AA01, aldosterone, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Aldosterone.]
[L01EX05, regorafenib, The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Regorafenib.]
[C01AA01, acetyldigitoxin, The serum concentration of Acetyldigitoxin can be increased when it is combined with Propylthiouracil.]
[L01AA09, bendamustine, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Bendamustine.]
[C08CA13, lercanidipine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Lercanidipine is combined with Propylthiouracil.]
[L04AA29, tofacitinib, Propylthiouracil may increase the immunosuppressive activities of Tofacitinib.]
[L01EX07, cabozantinib, The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Cabozantinib.]
[G04BE03, sildenafil, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Sildenafil is combined with Propylthiouracil.]
[L01EA05, ponatinib, The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Ponatinib.]
[B01AF02, apixaban, Propylthiouracil may increase the anticoagulant activities of Apixaban.]
[C03AA01, bendroflumethiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Propylthiouracil.]
[L04AX06, pomalidomide, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Pomalidomide.]
[L04AX07, dimethyl fumarate, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Dimethyl fumarate.]
[A10AE05, insulin detemir, The therapeutic efficacy of Insulin detemir can be decreased when used in combination with Propylthiouracil.]
[L04AA18, everolimus, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Everolimus.]
[L01EB03, afatinib, The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Afatinib.]
[N06AX28, levomilnacipran, The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Levomilnacipran.]
[L03AA14, lipegfilgrastim, Propylthiouracil may increase the myelosuppressive activities of Lipegfilgrastim.]
[L01EL01, ibrutinib, The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Ibrutinib.]
[C07AB04, acebutolol, The risk or severity of adverse effects can be increased when Acebutolol is combined with Propylthiouracil.]
[L04AA32, apremilast, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Apremilast.]
[S03BA03, betamethasone, The risk or severity of adverse effects can be increased when Betamethasone is combined with Propylthiouracil.]
[B01AE03, argatroban, Propylthiouracil may increase the anticoagulant activities of Argatroban.]
[C10AB02, bezafibrate, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propylthiouracil is combined with Bezafibrate.]
[L04AC11, siltuximab, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Siltuximab.]
[L01ED02, ceritinib, The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Ceritinib.]
[B01AC26, vorapaxar, Propylthiouracil may increase the anticoagulant activities of Vorapaxar.]
[L04AA33, vedolizumab, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Vedolizumab.]
[B01AA07, acenocoumarol, Propylthiouracil may increase the anticoagulant activities of Acenocoumarol.]
[L01XH04, belinostat, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Belinostat.]
[L01EM01, idelalisib, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Idelalisib.]
[L03AB13, peginterferon beta-1a, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Peginterferon beta-1a.]
[L01BC08, decitabine, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Decitabine.]
[L04AX05, pirfenidone, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Pirfenidone.]
[L01EX09, nintedanib, The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Nintedanib.]
[L01FX07, blinatumomab, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Blinatumomab.]
[L01XK01, olaparib, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Olaparib.]
[B01AA01, dicumarol, Propylthiouracil may increase the anticoagulant activities of Dicoumarol.]
[B01AF03, edoxaban, Propylthiouracil may increase the anticoagulant activities of Edoxaban.]
[L04AC10, secukinumab, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Secukinumab.]
[L01EF01, palbociclib, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Palbociclib.]
[L01EX08, lenvatinib, The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Lenvatinib.]
[L01XH03, panobinostat, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Panobinostat.]
[L01DC01, bleomycin, The risk or severity of adverse effects can be increased when Bleomycin is combined with Propylthiouracil.]
[B01AA11, tioclomarol, Propylthiouracil may increase the anticoagulant activities of Tioclomarol.]
[B01AC25, cangrelor, Propylthiouracil may increase the anticoagulant activities of Cangrelor.]
[A10AE06, insulin degludec, The therapeutic efficacy of Insulin degludec can be decreased when used in combination with Propylthiouracil.]
[C10AD06, acipimox, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propylthiouracil is combined with Acipimox.]
[L01CX01, trabectedin, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Trabectedin.]
[R03DX09, mepolizumab, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Mepolizumab.]
[L01EB04, osimertinib, The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Osimertinib.]
[L01ED03, alectinib, The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Alectinib.]
[A10BB31, acetohexamide, The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Propylthiouracil.]
[L04AC13, ixekizumab, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Ixekizumab.]
[N06AA19, amineptin, The risk or severity of Cardiac Arrhythmia can be increased when Propylthiouracil is combined with Amineptine.]
[C03CA02, bumetanide, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propylthiouracil is combined with Bumetanide.]
[L01AB01, busulfan, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Busulfan.]
[L01XX27, arsenic trioxide, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Arsenic trioxide.]
[L04AC12, brodalumab, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Brodalumab.]
[R03DA08, bamifylline, Propylthiouracil may decrease the excretion rate of Bamifylline which could result in a higher serum level.]
[L04AA36, ocrelizumab, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Ocrelizumab.]
[N06BC01, caffeine, Propylthiouracil may decrease the excretion rate of Caffeine which could result in a higher serum level.]
[L04AC01, daclizumab, The risk or severity of adverse effects can be increased when Daclizumab is combined with Propylthiouracil.]
[J01XX08, linezolid, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Linezolid.]
[L04AB02, infliximab, The risk or severity of adverse effects can be increased when Infliximab is combined with Propylthiouracil.]
[L01EX10, midostaurin, The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Midostaurin.]
[L01ED04, brigatinib, The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Brigatinib.]
[L04AC14, sarilumab, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Sarilumab.]
[B01AF04, betrixaban, Propylthiouracil may increase the anticoagulant activities of Betrixaban.]
[L04AC16, guselkumab, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Guselkumab.]
[L01BC06, capecitabine, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Capecitabine.]
[L01EH02, neratinib, The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Neratinib.]
[L01XH01, vorinostat, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Vorinostat.]
[L04AC02, basiliximab, The risk or severity of adverse effects can be increased when Basiliximab is combined with Propylthiouracil.]
[L01BA03, raltitrexed, The risk or severity of adverse effects can be increased when Raltitrexed is combined with Propylthiouracil.]
[V03AF08, palifermin, The therapeutic efficacy of Palifermin can be decreased when used in combination with Propylthiouracil.]
[R03BA02, budesonide, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Budesonide.]
[C04AX20, buflomedil, The risk or severity of bleeding can be increased when Buflomedil is combined with Propylthiouracil.]
[L01EL02, acalabrutinib, The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Acalabrutinib.]
[N06AA15, butriptyline, The risk or severity of Cardiac Arrhythmia can be increased when Propylthiouracil is combined with Butriptyline.]
[C01AA02, acetyldigoxins, The serum concentration of Acetyldigoxin can be increased when it is combined with Propylthiouracil.]
[C09AA01, captopril, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propylthiouracil is combined with Captopril.]
[V04CD06, macimorelin, The therapeutic efficacy of Macimorelin can be decreased when used in combination with Propylthiouracil.]
[N03AF01, carbamazepine, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Carbamazepine.]
[H03BB01, carbimazole, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Carbimazole is combined with Propylthiouracil.]
[L03AB06, interferon alfa-n1, The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Propylthiouracil.]
[B02BX09, fostamatinib, The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Fostamatinib.]
[L04AA37, baricitinib, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Baricitinib.]
[C07AB08, celiprolol, The risk or severity of adverse effects can be increased when Celiprolol is combined with Propylthiouracil.]
[L01EB07, dacomitinib, The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Dacomitinib.]
[A10BB06, carbutamide, The therapeutic efficacy of Carbutamide can be decreased when used in combination with Propylthiouracil.]
[R03DA02, oxtriphylline, Propylthiouracil may decrease the excretion rate of Oxtriphylline which could result in a higher serum level.]
[L04AA39, emapalumab, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Emapalumab.]
[L01AD01, carmustine, The risk or severity of adverse effects can be increased when Carmustine is combined with Propylthiouracil.]
[L01EX12, larotrectinib, The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Larotrectinib.]
[L01EX13, gilteritinib, The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Gilteritinib.]
[L04AA43, ravulizumab, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Ravulizumab.]
[B01AX07, caplacizumab, The risk or severity of bleeding can be increased when Caplacizumab is combined with Propylthiouracil.]
[B01AC23, cilostazol, The risk or severity of bleeding can be increased when Cilostazol is combined with Propylthiouracil.]
[C10AB08, ciprofibrate, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propylthiouracil is combined with Ciprofibrate.]
[L04AA42, siponimod, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Siponimod.]
[L01EN01, erdafitinib, The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Erdafitinib.]
[H02AB14, cloprednol, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Cloprednol.]
[C01EB09, ubidecarenone, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propylthiouracil is combined with Ubidecarenone.]
[L04AB01, etanercept, The risk or severity of adverse effects can be increased when Etanercept is combined with Propylthiouracil.]
[H02AB17, cortivazol, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Cortivazol.]
[L04AC18, risankizumab, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Risankizumab.]
[L01EX15, pexidartinib, The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Pexidartinib.]
[L04AA44, upadacitinib, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Upadacitinib.]
[L01EJ02, fedratinib, The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Fedratinib.]
[L01EX14, entrectinib, The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Entrectinib.]
[C03AA09, cyclothiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclothiazide is combined with Propylthiouracil.]
[A10AE03, insulin, regular, pork, The therapeutic efficacy of Insulin pork can be decreased when used in combination with Propylthiouracil.]
[J01XX09, daptomycin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Propylthiouracil.]
[H02AB13, deflazacort, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Deflazacort.]
[L01FD01, trastuzumab, Trastuzumab may increase the neutropenic activities of Propylthiouracil.]
[L01FD03, ado-trastuzumab emtansine, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Trastuzumab emtansine.]
[L04AX09, diroximel fumarate, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Diroximel fumarate.]
[L01EX18, avapritinib, The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Avapritinib.]
[L04AA53, teprotumumab, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Teprotumumab.]
[L04AA38, ozanimod, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Ozanimod.]
[L01EE04, selumetinib, The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Selumetinib.]
[L01XF03, bexarotene, The risk or severity of adverse effects can be increased when Bexarotene is combined with Propylthiouracil.]
[L01AA02, chlorambucil, The risk or severity of adverse effects can be increased when Chlorambucil is combined with Propylthiouracil.]
[S03AA08, chloramphenicol, The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Propylthiouracil.]
[L01EH03, tucatinib, The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Tucatinib.]
[L01EX17, capmatinib, The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Capmatinib.]
[D07XB03, fluprednidene, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Fluprednidene.]
[L01EX22, selpercatinib, The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Selpercatinib.]
[B01AE02, lepirudin, Propylthiouracil may increase the anticoagulant activities of Lepirudin.]
[L04AA47, inebilizumab, The risk or severity of infection can be increased when Propylthiouracil is combined with Inebilizumab.]
[R05CB11, stepronin, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Stepronin.]
[L04AC19, satralizumab, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Satralizumab.]
[P01BA01, chloroquine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propylthiouracil is combined with Chloroquine.]
[C03AA04, chlorothiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Chlorothiazide is combined with Propylthiouracil.]
[A10BB02, chlorpropamide, The therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Propylthiouracil.]
[C10AB09, etofibrate, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propylthiouracil is combined with Etofibrate.]
[L01BB05, fludarabine, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Fludarabine.]
[L04AD03, voclosporin, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Voclosporin.]
[L01EX21, tepotinib, The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Tepotinib.]
[N06BA10, fenethylline, Propylthiouracil may decrease the excretion rate of Fenethylline which could result in a higher serum level.]
[N06BA08, fenozolone, The risk or severity of adverse effects can be increased when Fenozolone is combined with Propylthiouracil.]
[R03BA03, flunisolide, The risk or severity of adverse effects can be increased when Flunisolide is combined with Propylthiouracil.]
[S02BA08, fluocinolone acetonide, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Fluocinolone acetonide.]
[A10AF01, insulin, regular, human, The therapeutic efficacy of Insulin human can be decreased when used in combination with Propylthiouracil.]
[L04AA50, ponesimod, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Ponesimod.]
[L01EK03, tivozanib, The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Tivozanib.]
[L03AB10, peginterferon alfa-2b, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Propylthiouracil.]
[A02BA01, cimetidine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cimetidine is combined with Propylthiouracil.]
[L01EN03, infigratinib, The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Infigratinib.]
[S03AA07, ciprofloxacin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ciprofloxacin is combined with Propylthiouracil.]
[L01XA01, cisplatin, The risk or severity of adverse effects can be increased when Cisplatin is combined with Propylthiouracil.]
[N06AB04, citalopram, The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Citalopram.]
[L04AA54, pegcetacoplan, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Pegcetacoplan.]
[L04AA48, belumosudil, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Belumosudil.]
[L04AA51, anifrolumab, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Anifrolumab.]
[A10BB12, glimepiride, The therapeutic efficacy of Glimepiride can be decreased when used in combination with Propylthiouracil.]
[A10BB08, gliquidone, The therapeutic efficacy of Gliquidone can be decreased when used in combination with Propylthiouracil.]
[R03CC13, clenbuterol, The risk or severity of adverse effects can be increased when Clenbuterol is combined with Propylthiouracil.]
[L03AB15, ropeginterferon alfa-2b, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Ropeginterferon alfa-2b.]
[B01AD11, tenecteplase, Propylthiouracil may increase the anticoagulant activities of Tenecteplase.]
[C10AB01, clofibrate, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propylthiouracil is combined with Clofibrate.]
[L01EJ03, pacritinib, The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Pacritinib.]
[N06AA04, clomipramine, The risk or severity of Cardiac Arrhythmia can be increased when Propylthiouracil is combined with Clomipramine.]
[L04AC22, spesolimab, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Spesolimab.]
[L04AA56, deucravacitinib, The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Deucravacitinib.]
[N05AH02, clozapine, The risk or severity of neutropenia can be increased when Propylthiouracil is combined with Clozapine.]
[L04AC21, bimekizumab, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Bimekizumab.]
[M04AC01, colchicine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propylthiouracil is combined with Colchicine.]
[L04AA13, leflunomide, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Leflunomide.]
[L01BB07, nelarabine, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Nelarabine.]
[A10AE04, insulin glargine, The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Propylthiouracil.]
[R03BA08, ciclesonide, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Ciclesonide.]
[B01AC10, indobufen, The risk or severity of bleeding can be increased when Indobufen is combined with Propylthiouracil.]
[C01AA06, lanatoside C, The serum concentration of Lanatoside C can be increased when it is combined with Propylthiouracil.]
[B01AB12, bemiparin, Propylthiouracil may increase the anticoagulant activities of Bemiparin.]
[L01EA01, imatinib, The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Imatinib.]
[H01CA02, nafarelin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propylthiouracil is combined with Nafarelin.]
[A03AA04, mebeverine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propylthiouracil is combined with Mebeverine.]
[A08AA09, mefenorex, The risk or severity of adverse effects can be increased when Mefenorex is combined with Propylthiouracil.]
[H02AB15, meprednisone, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Meprednisone.]
[R03CB02, methoxyphenamine, The risk or severity of adverse effects can be increased when Methoxyphenamine is combined with Propylthiouracil.]
[L04AA15, alefacept, The risk or severity of adverse effects can be increased when Alefacept is combined with Propylthiouracil.]
[C03AA07, cyclopenthiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclopenthiazide is combined with Propylthiouracil.]
[L01AA01, cyclophosphamide, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Propylthiouracil.]
[S01XA18, cyclosporine, Propylthiouracil may increase the immunosuppressive activities of Cyclosporine.]
[C10AA07, rosuvastatin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propylthiouracil is combined with Rosuvastatin.]
[L01BC01, cytarabine, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Cytarabine.]
[L01AX04, dacarbazine, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Dacarbazine.]
[L01DA01, dactinomycin, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Dactinomycin.]
[L01DB02, daunorubicin, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Daunorubicin.]
[N06AX06, nefazodone, The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Nefazodone.]
[C01CA23, theodrenaline, Propylthiouracil may decrease the excretion rate of Theodrenaline which could result in a higher serum level.]
[B01AX05, fondaparinux, Propylthiouracil may increase the anticoagulant activities of Fondaparinux.]
[D11AH02, pimecrolimus, The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Propylthiouracil.]
[N06AB10, escitalopram, The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Escitalopram.]
[N06AA01, desipramine, The risk or severity of Cardiac Arrhythmia can be increased when Propylthiouracil is combined with Desipramine.]
[C01AA07, deslanoside, The serum concentration of Deslanoside can be increased when it is combined with Propylthiouracil.]
[D07XC02, desoximetasone, The risk or severity of adverse effects can be increased when Desoximetasone is combined with Propylthiouracil.]
[L01XA03, oxaliplatin, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Propylthiouracil.]
[S03BA01, dexamethasone, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Dexamethasone.]
[L04AB04, adalimumab, The risk or severity of adverse effects can be increased when Adalimumab is combined with Propylthiouracil.]
[L01EB01, gefitinib, The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Gefitinib.]
[N06BA02, dextroamphetamine, The risk or severity of adverse effects can be increased when Amphetamine is combined with Propylthiouracil.]
[N06AB05, paroxetine, The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Paroxetine.]
[B01AC04, clopidogrel, The risk or severity of bleeding can be increased when Clopidogrel is combined with Propylthiouracil.]
[C04AD01, pentifylline, Propylthiouracil may decrease the excretion rate of Pentifylline which could result in a higher serum level.]
[N05BA01, diazepam, The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Diazepam.]
[N06AA08, dibenzepin, The risk or severity of Cardiac Arrhythmia can be increased when Propylthiouracil is combined with Dibenzepin.]
[L01DC04, ixabepilone, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Ixabepilone.]
[L01EB02, erlotinib, The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Erlotinib.]
[L01DB08, pirarubicin, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Pirarubicin.]
[A08AA03, diethylpropion, The risk or severity of adverse effects can be increased when Diethylpropion is combined with Propylthiouracil.]
[D07XC04, diflucortolone, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Difluocortolone.]
[C01AA04, digitoxin, The serum concentration of Digitoxin can be increased when it is combined with Propylthiouracil.]
[C01AA05, digoxin, The serum concentration of Digoxin can be increased when it is combined with Propylthiouracil.]
[L01XX24, pegaspargase, The risk or severity of adverse effects can be increased when Pegaspargase is combined with Propylthiouracil.]
[L04AX04, lenalidomide, The risk or severity of adverse effects can be increased when Lenalidomide is combined with Propylthiouracil.]
[R03CC08, procaterol, The risk or severity of adverse effects can be increased when Procaterol is combined with Propylthiouracil.]
[N06BC02, propentofylline, Propylthiouracil may decrease the excretion rate of Propentofylline which could result in a higher serum level.]
[R03DA03, proxyphylline, Propylthiouracil may decrease the excretion rate of Proxyphylline which could result in a higher serum level.]
[B01AC07, dipyridamole, Propylthiouracil may increase the anticoagulant activities of Dipyridamole.]
[B01AD10, drotrecogin alfa, Propylthiouracil may increase the anticoagulant activities of Drotrecogin alfa.]
[N06AA23, quinupramine, The risk or severity of Cardiac Arrhythmia can be increased when Propylthiouracil is combined with Quinupramine.]
[S01XA23, sirolimus, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Sirolimus.]
[S01AX06, resorcinol, The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Resorcinol.]
[L04AA23, natalizumab, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Natalizumab.]
[L04AA21, efalizumab, The risk or severity of adverse effects can be increased when Efalizumab is combined with Propylthiouracil.]
[L01EX01, sunitinib, The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Sunitinib.]
[L01XG01, bortezomib, The risk or severity of adverse effects can be increased when Bortezomib is combined with Propylthiouracil.]
[R03AC12, salmeterol, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propylthiouracil is combined with Salmeterol.]
[C01CA07, dobutamine, The risk or severity of adverse effects can be increased when Dobutamine is combined with Propylthiouracil.]
[C01CA04, dopamine, The risk or severity of adverse effects can be increased when Dopamine is combined with Propylthiouracil.]
[N06AA16, dothiepin, The risk or severity of Cardiac Arrhythmia can be increased when Propylthiouracil is combined with Dosulepin.]
[N06AA12, doxepin, The risk or severity of Cardiac Arrhythmia can be increased when Propylthiouracil is combined with Doxepin.]
[L01DB01, doxorubicin, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Doxorubicin.]
[N06AB06, sertraline, The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Sertraline.]
[A08AA10, sibutramine, The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Sibutramine.]
[C10AA01, simvastatin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propylthiouracil is combined with Simvastatin.]
[R03DA01, dyphylline, Propylthiouracil may decrease the excretion rate of Dyphylline which could result in a higher serum level.]
[H01AA01, corticotropin, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Corticotropin.]
[L01AX03, temozolomide, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Temozolomide.]
[D01BA02, terbinafine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propylthiouracil is combined with Terbinafine.]
[S01GA02, tetrahydrozoline, The risk or severity of adverse effects can be increased when Tetryzoline is combined with Propylthiouracil.]
[P01AX02, emetine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propylthiouracil is combined with Emetine.]
[N06AX14, tianeptine, The risk or severity of Cardiac Arrhythmia can be increased when Propylthiouracil is combined with Tianeptine.]
[C09AA02, enalapril, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propylthiouracil is combined with Enalapril.]
[R01AA09, tramazoline, The risk or severity of adverse effects can be increased when Tramazoline is combined with Propylthiouracil.]
[B01AC18, triflusal, Propylthiouracil may increase the anticoagulant activities of Triflusal.]
[H02CA01, trilostane, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Trilostane.]
[L01AA07, trofosfamide, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Trofosfamide.]
[C05CA04, troxerutin, Propylthiouracil may increase the anticoagulant activities of Troxerutin.]
[L01CA04, vinorelbine, The risk or severity of adverse effects can be increased when Vinorelbine is combined with Propylthiouracil.]
[S01FB02, ephedrine, The risk or severity of adverse effects can be increased when Ephedrine is combined with Propylthiouracil.]
[S01EA01, epinephrine, The risk or severity of adverse effects can be increased when Epinephrine is combined with Propylthiouracil.]
[L01DB03, epirubicin, The risk or severity of adverse effects can be increased when Epirubicin is combined with Propylthiouracil.]
[A10AB06, insulin glulisine, human, The therapeutic efficacy of Insulin glulisine can be decreased when used in combination with Propylthiouracil.]
[B01AD03, anistreplase, Propylthiouracil may increase the anticoagulant activities of Anistreplase.]
[L01XA02, carboplatin, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Carboplatin.]
[B01AC11, iloprost, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propylthiouracil is combined with Iloprost.]
[L01XX11, estramustine, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Estramustine.]
[R03BA09, fluticasone furoate, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Fluticasone furoate.]
[R03BA05, fluticasone, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Fluticasone.]
[C10AA04, fluvastatin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propylthiouracil is combined with Fluvastatin.]
[C01CA15, gepefrine, The risk or severity of adverse effects can be increased when Gepefrine is combined with Propylthiouracil.]
[J04AD03, ethionamide, The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Ethionamide.]
[C01CA01, etilefrine, The risk or severity of adverse effects can be increased when Etilefrine is combined with Propylthiouracil.]
[L01CB01, etoposide, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Etoposide.]
[L04AD02, tacrolimus, Tacrolimus may increase the immunosuppressive activities of Propylthiouracil.]
[A02BA04, nizatidine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propylthiouracil is combined with Nizatidine.]
[N06AB08, fluvoxamine, The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Fluvoxamine.]
[L02AE02, leuprolide, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Propylthiouracil.]
[L04AA02, muromonab-CD3, The risk or severity of adverse effects can be increased when Muromonab is combined with Propylthiouracil.]
[C10AA03, pravastatin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pravastatin is combined with Propylthiouracil.]
[B05AA05, dextran, Propylthiouracil may increase the anticoagulant activities of Dextran.]
[V03AF02, dexrazoxane, The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Propylthiouracil.]
[R03CC04, fenoterol, The risk or severity of adverse effects can be increased when Fenoterol is combined with Propylthiouracil.]
[B01AD05, plasmin, Propylthiouracil may increase the anticoagulant activities of Fibrinolysin.]
[L01BB06, clofarabine, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Clofarabine.]
[L04AA40, cladribine, The risk or severity of adverse effects can be increased when Cladribine is combined with Propylthiouracil.]
[J02AX01, flucytosine, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Flucytosine.]
[H02AA02, fludrocortisone, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Fludrocortisone.]
[D07AC08, fluocinonide, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Fluocinonide.]
[N06AA14, melitracen, The risk or severity of Cardiac Arrhythmia can be increased when Propylthiouracil is combined with Melitracen.]
[H02AB03, fluocortolone, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Fluocortolone.]
[V03AZ01, ethanol, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propylthiouracil is combined with Ethanol.]
[L01BC09, floxuridine, The risk or severity of adverse effects can be increased when Floxuridine is combined with Propylthiouracil.]
[S01CB05, fluorometholone, The risk or severity of adverse effects can be increased when Fluorometholone is combined with Propylthiouracil.]
[L01BC02, fluorouracil, The risk or severity of adverse effects can be increased when Fluorouracil is combined with Propylthiouracil.]
[N06AB03, fluoxetine, The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Fluoxetine.]
[N05AF01, flupenthixol, The risk or severity of myelosuppression can be increased when Flupentixol is combined with Propylthiouracil.]
[M05BA04, alendronic acid, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propylthiouracil is combined with Alendronic acid.]
[S01AD09, ganciclovir, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propylthiouracil is combined with Ganciclovir.]
[C10AB04, gemfibrozil, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propylthiouracil is combined with Gemfibrozil.]
[L01EA02, dasatinib, The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Dasatinib.]
[C01CA21, cafedrine, Propylthiouracil may decrease the excretion rate of Cafedrine which could result in a higher serum level.]
[L01EH01, lapatinib, The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Lapatinib.]
[A10BB01, glyburide, The therapeutic efficacy of Glyburide can be decreased when used in combination with Propylthiouracil.]
[A10BB09, gliclazide, The therapeutic efficacy of Gliclazide can be decreased when used in combination with Propylthiouracil.]
[A10BB07, glipizide, The therapeutic efficacy of Glipizide can be decreased when used in combination with Propylthiouracil.]
[L01EX02, sorafenib, The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Sorafenib.]
[B01AA12, fluindione, Propylthiouracil may increase the anticoagulant activities of Fluindione.]
[A10AD05, insulin aspart, human, The therapeutic efficacy of Insulin aspart can be decreased when used in combination with Propylthiouracil.]
[L01CE02, irinotecan, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Irinotecan.]
[M04AA01, allopurinol, The risk or severity of adverse effects can be increased when Allopurinol is combined with Propylthiouracil.]
[S01XA14, heparin, Propylthiouracil may increase the anticoagulant activities of Heparin.]
[L01XX03, altretamine, The risk or severity of adverse effects can be increased when Altretamine is combined with Propylthiouracil.]
[M02AA26, nimesulide, The risk or severity of bleeding can be increased when Nimesulide is combined with Propylthiouracil.]
[C03AA03, hydrochlorothiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Hydrochlorothiazide is combined with Propylthiouracil.]
[D07AB02, hydrocortisone butyrate, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Hydrocortisone butyrate.]
[C03AA02, hydroflumethiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Hydroflumethiazide is combined with Propylthiouracil.]
[P01BA02, hydroxychloroquine, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Hydroxychloroquine.]
[L01XX05, hydroxyurea, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Hydroxyurea.]
[M05BA07, risedronic acid, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propylthiouracil is combined with Risedronic acid.]
[B05CB02, sodium citrate, Propylthiouracil may increase the anticoagulant activities of Sodium citrate.]
[L01DB06, idarubicin, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Idarubicin.]
[L01AA06, ifosfamide, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Ifosfamide.]
[N06AA02, imipramine, The risk or severity of Cardiac Arrhythmia can be increased when Propylthiouracil is combined with Imipramine.]
[L01CD01, paclitaxel, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Paclitaxel.]
[R01AD07, tixocortol, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Tixocortol.]
[L01CE01, topotecan, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Topotecan.]
[S01BC01, indomethacin, The risk or severity of adverse effects can be increased when Indomethacin is combined with Propylthiouracil.]
[L03AB04, interferon alfa-2a, The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Propylthiouracil.]
[L03AB05, interferon alfa-2b, The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Propylthiouracil.]
[N06AX17, milnacipran, The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Milnacipran.]
[L04AA25, eculizumab, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Eculizumab.]
[C10AA06, cerivastatin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cerivastatin is combined with Propylthiouracil.]
[L01XX35, anagrelide, The risk or severity of bleeding can be increased when Anagrelide is combined with Propylthiouracil.]
[L03AB09, interferon alfacon-1, The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Propylthiouracil.]
[V03AB01, ipecac, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propylthiouracil is combined with Ipecac.]
[J05AF04, stavudine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propylthiouracil is combined with Stavudine.]
[N06AA13, iprindole, The risk or severity of Cardiac Arrhythmia can be increased when Propylthiouracil is combined with Iprindole.]
[J04AC01, isoniazid, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propylthiouracil is combined with Isoniazid.]
[R03CB01, isoproterenol, The risk or severity of adverse effects can be increased when Isoprenaline is combined with Propylthiouracil.]
[D10BA01, isotretinoin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propylthiouracil is combined with Isotretinoin.]
[C04AA01, isoxsuprine, The risk or severity of adverse effects can be increased when Isoxsuprine is combined with Propylthiouracil.]
[P02CF01, ivermectin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propylthiouracil is combined with Ivermectin.]
[B01AE06, bivalirudin, Propylthiouracil may increase the anticoagulant activities of Bivalirudin.]
[H01AC01, somatropin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Somatotropin is combined with Propylthiouracil.]
[L04AC07, tocilizumab, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Tocilizumab.]
[C02KD01, ketanserin, The risk or severity of bleeding can be increased when Ketanserin is combined with Propylthiouracil.]
[B01AC22, prasugrel, Propylthiouracil may increase the anticoagulant activities of Prasugrel.]
[L04AA24, abatacept, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Abatacept.]
[C07AG01, labetalol, The risk or severity of adverse effects can be increased when Labetalol is combined with Propylthiouracil.]
[L01DC03, mitomycin, The risk or severity of adverse effects can be increased when Mitomycin is combined with Propylthiouracil.]
[N06AA07, lofepramine, The risk or severity of Cardiac Arrhythmia can be increased when Propylthiouracil is combined with Lofepramine.]
[L01AD02, lomustine, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Lomustine.]
[C10AA02, lovastatin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Lovastatin is combined with Propylthiouracil.]
[L01EG01, temsirolimus, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Temsirolimus.]
[L01BA05, pralatrexate, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Pralatrexate.]
[L01EA03, nilotinib, The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Nilotinib.]
[L01AA05, mechlorethamine, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Mechlorethamine.]
[C01AA08, medigoxin, The serum concentration of Metildigoxin can be increased when it is combined with Propylthiouracil.]
[P01BC02, mefloquine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Mefloquine is combined with Propylthiouracil.]
[B01AB06, nadroparin, Propylthiouracil may increase the anticoagulant activities of Nadroparin.]
[B01AB05, enoxaparin, Propylthiouracil may increase the anticoagulant activities of Enoxaparin.]
[B01AB04, dalteparin, Propylthiouracil may increase the anticoagulant activities of Dalteparin.]
[L01AA03, melphalan, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Melphalan.]
[C01CA11, mephentermine, The risk or severity of adverse effects can be increased when Mephentermine is combined with Propylthiouracil.]
[C01CA09, metaraminol, The risk or severity of adverse effects can be increased when Metaraminol is combined with Propylthiouracil.]
[N06BA03, methamphetamine, The risk or severity of adverse effects can be increased when Metamfetamine is combined with Propylthiouracil.]
[J05AF05, lamivudine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propylthiouracil is combined with Lamivudine.]
[H03BB02, methimazole, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Methimazole.]
[L01BA04, pemetrexed, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Pemetrexed.]
[L04AX03, methotrexate, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Methotrexate.]
[C01CA10, methoxamine, The risk or severity of adverse effects can be increased when Methoxamine is combined with Propylthiouracil.]
[C03AA08, methyclothiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Propylthiouracil.]
[C02AB01, methyldopa, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propylthiouracil is combined with Methyldopa.]
[R03DA05, aminophylline, Propylthiouracil may decrease the excretion rate of Aminophylline which could result in a higher serum level.]
[H02AB04, methylprednisolone, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Methylprednisolone.]
[A03FA01, metoclopramide, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propylthiouracil is combined with Metoclopramide.]
[B01AB07, parnaparin, Propylthiouracil may increase the anticoagulant activities of Parnaparin.]
[C01CA17, midodrine, The risk or severity of adverse effects can be increased when Midodrine is combined with Propylthiouracil.]
[B01AB10, tinzaparin, Propylthiouracil may increase the anticoagulant activities of Tinzaparin.]
[J01AA08, minocycline, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propylthiouracil is combined with Minocycline.]
[L01DB07, mitoxantrone, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Mitoxantrone.]
[N06BA12, lisdexamfetamine, The risk or severity of adverse effects can be increased when Lisdexamfetamine is combined with Propylthiouracil.]
[L03AC01, aldesleukin, The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Aldesleukin.]
[C01BD01, amiodarone, The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Amiodarone.]
[N06AA09, amitriptyline, The risk or severity of Cardiac Arrhythmia can be increased when Propylthiouracil is combined with Amitriptyline.]
[L04AB05, certolizumab pegol, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Certolizumab pegol.]
[L04AA52, ofatumumab, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Ofatumumab.]
[L01EX03, pazopanib, The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Pazopanib.]
[L04AA06, mycophenolic acid, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Mycophenolic acid.]
[J05AJ01, raltegravir, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propylthiouracil is combined with Raltegravir.]
[N06AA17, amoxapine, The risk or severity of Cardiac Arrhythmia can be increased when Propylthiouracil is combined with Amoxapine.]
[L03AB08, interferon beta-1b, The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Propylthiouracil.]
[N07BB04, naltrexone, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propylthiouracil is combined with Naltrexone.]
[L04AC03, anakinra, The risk or severity of adverse effects can be increased when Anakinra is combined with Propylthiouracil.]
[S01GA01, naphazoline, The risk or severity of adverse effects can be increased when Naphazoline is combined with Propylthiouracil.]
[N06BA01, amphetamine, The risk or severity of adverse effects can be increased when Amphetamine is combined with Propylthiouracil.]
[N06AX21, duloxetine, The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Duloxetine.]
[L01CD02, docetaxel, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Docetaxel.]
[L02BG04, letrozole, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propylthiouracil is combined with Letrozole.]
[B01AC17, tirofiban, The risk or severity of bleeding can be increased when Tirofiban is combined with Propylthiouracil.]
[J02AA01, amphotericin B, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propylthiouracil is combined with Amphotericin B.]
[N06AX23, desvenlafaxine, The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Desvenlafaxine.]
[L01XX01, amsacrine, The risk or severity of adverse effects can be increased when Amsacrine is combined with Propylthiouracil.]
[C10AD02, niacin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propylthiouracil is combined with Niacin.]
[C01CA03, norepinephrine, The risk or severity of adverse effects can be increased when Norepinephrine is combined with Propylthiouracil.]
[S01AE02, norfloxacin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propylthiouracil is combined with Norfloxacin.]
[N06AA10, nortriptyline, The risk or severity of Cardiac Arrhythmia can be increased when Propylthiouracil is combined with Nortriptyline.]
[B01AC16, eptifibatide, The risk or severity of bleeding can be increased when Eptifibatide is combined with Propylthiouracil.]
[G02CA02, nylidrin, The risk or severity of adverse effects can be increased when Nylidrin is combined with Propylthiouracil.]
[B01AB08, reviparin, Propylthiouracil may increase the anticoagulant activities of Reviparin.]
[S02AA16, ofloxacin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propylthiouracil is combined with Ofloxacin.]
[L04AC04, rilonacept, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Rilonacept.]
[N06AA05, opipramol, The risk or severity of Cardiac Arrhythmia can be increased when Propylthiouracil is combined with Opipramol.]
[R03CB03, metaproterenol, The risk or severity of adverse effects can be increased when Orciprenaline is combined with Propylthiouracil.]
[B01AD07, reteplase, Propylthiouracil may increase the anticoagulant activities of Reteplase.]
[B01AD09, ancrod, Propylthiouracil may increase the anticoagulant activities of Ancrod.]
[C01AC01, ouabain, The serum concentration of Ouabain can be increased when it is combined with Propylthiouracil.]
[S01GA04, oxymetazoline, The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Propylthiouracil.]
[J04AA01, aminosalicylic acid, The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Aminosalicylic acid.]
[B01AB09, danaparoid, Propylthiouracil may increase the anticoagulant activities of Danaparoid.]
[H02AB05, paramethasone, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Paramethasone.]
[M01CC01, penicillamine, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Penicillamine.]
[J07AF01, diphtheria toxoid vaccine, inactivated, The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Propylthiouracil.]
[J07AM01, tetanus toxoid vaccine, inactivated, The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Propylthiouracil.]
[L01XX08, pentostatin, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Pentostatin.]
[C04AD03, pentoxifylline, Propylthiouracil may decrease the excretion rate of Pentoxifylline which could result in a higher serum level.]
[N05AB03, perphenazine, The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Perphenazine.]
[J07AJ, pertussis vaccine, The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Propylthiouracil.]
[B01AA02, phenindione, Propylthiouracil may increase the anticoagulant activities of Phenindione.]
[B01AA04, phenprocoumon, Propylthiouracil may increase the anticoagulant activities of Phenprocoumon.]
[A08AA01, phentermine, The risk or severity of adverse effects can be increased when Phentermine is combined with Propylthiouracil.]
[S01GA05, phenylephrine, The risk or severity of adverse effects can be increased when Phenylephrine is combined with Propylthiouracil.]
[R01BA01, phenylpropanolamine, The risk or severity of adverse effects can be increased when Phenylpropanolamine is combined with Propylthiouracil.]
[N03AB02, phenytoin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Phenytoin is combined with Propylthiouracil.]
[L04AB06, golimumab, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Golimumab.]
[C10AA05, atorvastatin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propylthiouracil is combined with Atorvastatin.]
[J05AE01, saquinavir, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propylthiouracil is combined with Saquinavir.]
[C09CA02, eprosartan, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propylthiouracil is combined with Eprosartan.]
[B01AC13, abciximab, Propylthiouracil may increase the anticoagulant activities of Abciximab.]
[S01XA13, alteplase, Propylthiouracil may increase the anticoagulant activities of Alteplase.]
[L04AC08, canakinumab, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Canakinumab.]
[C03AA05, polythiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Polythiazide is combined with Propylthiouracil.]
[J05AE03, ritonavir, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ritonavir is combined with Propylthiouracil.]
[A10AD04, insulin lispro, The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Propylthiouracil.]
[C10AA08, pitavastatin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propylthiouracil is combined with Pitavastatin.]
[S03BA02, prednisolone, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Prednisolone.]
[H02AB07, prednisone, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Prednisone.]
[C01BA02, procainamide, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propylthiouracil is combined with Procainamide.]
[L01XB01, procarbazine, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Procarbazine.]
[C10AB05, fenofibrate, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propylthiouracil is combined with Fenofibrate.]
[N01AX10, propofol, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propylthiouracil is combined with Propofol.]
[L04AA03, lymphocyte immune globulin, anti-thymocyte globulin, equine, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Antilymphocyte immunoglobulin (horse).]
[C01AB01, proscillaridin, The serum concentration of Proscillaridin can be increased when it is combined with Propylthiouracil.]
[B01AC09, epoprostenol, Propylthiouracil may increase the anticoagulant activities of Epoprostenol.]
[R03DC03, montelukast, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Montelukast is combined with Propylthiouracil.]
[N06AA11, protriptyline, The risk or severity of Cardiac Arrhythmia can be increased when Propylthiouracil is combined with Protriptyline.]
[R01BA02, pseudoephedrine, The risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Propylthiouracil.]
[J06BB05, rabies immune globulin, human, The therapeutic efficacy of Rabies immune globulin, human can be decreased when used in combination with Propylthiouracil.]
[A02BA02, ranitidine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propylthiouracil is combined with Ranitidine.]
[G02CA01, ritodrine, The risk or severity of adverse effects can be increased when Ritodrine is combined with Propylthiouracil.]
[A07EC01, sulfasalazine, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Sulfasalazine.]
[L01FA03, obinutuzumab, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Obinutuzumab.]
[V10XA01, sodium iodide I131, The therapeutic efficacy of Iodide I-131 can be decreased when used in combination with Propylthiouracil.]
[M05BX04, denosumab, The risk or severity of adverse effects can be increased when Denosumab is combined with Propylthiouracil.]
[L01CD04, cabazitaxel, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Cabazitaxel.]
[L03AX17, sipuleucel-T, The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Propylthiouracil.]
